^
BIOMARKER:

EGFR L858R

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
Invest New Drugs - 1 week
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
EGFR L858R
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
EGFR L858R
NSCLC
icotinib
Sensitive: B - Late Trials
EGFR L858R
NSCLC
gefitinib + rivoceranib
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
EGFR L858R
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR L858R
LUAD
erlotinib
Resistant: B - Late Trials
EGFR L858R
NSCLC
gefitinib + ramucirumab
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Small Cell Squamous Cancer
erlotinib
Sensitive: B - Late Trials
EGFR L858R
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR L858R
NSCLC
aumolertinib
Sensitive: B - Late Trials
EGFR L858R
LUAD
afatinib
Sensitive: B - Late Trials
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive: C1 - Off-label
EGFR L858R
LUAD
osimertinib
Sensitive: C1 - Off-label
EGFR L858R
NSCLC
bevacizumab
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
osimertinib + ABT 263
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
gefitinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
osimertinib + gefitinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
anlotinib + icotinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
EGF816
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
osimertinib + savolitinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
bevacizumab + erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
Lung Cancer
crizotinib + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
rociletinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
amivantamab-vmjw + lazertinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
Lung Cancer
bevacizumab + erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
U3-1402
Sensitive: C2 – Inclusion Criteria
EGFR L858R
Lung Cancer
icotinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR L858R
LUAD
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
afatinib + DFP-14323
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
osimertinib + MEDI9447
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
gefitinib + durvalumab
Resistant: C3 – Early Trials
EGFR L858R
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
cisplatin + erlotinib + docetaxel
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
olaparib + gefitinib
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
erlotinib + anlotinib
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
anlotinib + APL-502
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
gefitinib + anlotinib
Sensitive: C3 – Early Trials
EGFR L858R
NSCLC
bevacizumab + icotinib
Sensitive: C3 – Early Trials
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
EGFR L858R
Germ Cell Tumors
icotinib
Sensitive: C4 – Case Studies
EGFR L858R
NSCLC
CH7233163
Sensitive: D – Preclinical
EGFR L858R
NSCLC
erlotinib + ado-trastuzumab emtansine
Sensitive: D – Preclinical
EGFR L858R
NSCLC
neratinib + PF-05212384
Sensitive: D – Preclinical
EGFR L858R
NSCLC
neratinib
Sensitive: D – Preclinical
EGFR L858R
Lung Cancer
BMS-722782
Sensitive: D – Preclinical
EGFR L858R
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR L858R
Colon Cancer
cetuximab
Sensitive: D – Preclinical